Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Equity Average (2016 - 2025)

IGC Pharma (IGC) has disclosed Equity Average for 15 consecutive years, with $7.1 million as the latest value for Q3 2025.

  • Quarterly Equity Average fell 7.12% to $7.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Sep 2025, down 7.12% year-over-year, with the annual reading at $6.8 million for FY2025, 38.6% down from the prior year.
  • Equity Average for Q3 2025 was $7.1 million at IGC Pharma, up from $6.2 million in the prior quarter.
  • The five-year high for Equity Average was $32.3 million in Q2 2021, with the low at $6.2 million in Q2 2025.
  • Average Equity Average over 5 years is $16.7 million, with a median of $14.1 million recorded in 2023.
  • The sharpest move saw Equity Average soared 34.75% in 2021, then crashed 50.72% in 2024.
  • Over 5 years, Equity Average stood at $30.4 million in 2021, then crashed by 36.67% to $19.2 million in 2022, then tumbled by 39.81% to $11.6 million in 2023, then crashed by 41.1% to $6.8 million in 2024, then increased by 3.92% to $7.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $7.1 million, $6.2 million, and $6.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.